Kkr Biosimilar Gp Llc - Net Worth and Insider Trading

Kkr Biosimilar Gp Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kkr Biosimilar Gp Llc owns 1 companies in total, including Coherus BioSciences Inc (CHRS) .

Click here to see the complete history of Kkr Biosimilar Gp Llc’s form 4 insider trades.

Insider Ownership Summary of Kkr Biosimilar Gp Llc

Ticker	Comapny	Transaction Date	Type of Owner
CHRS	Coherus BioSciences Inc	2014-11-06	10 percent owner

Kkr Biosimilar Gp Llc Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Kkr Biosimilar Gp Llc Ownership Network

Ownership Network List of Kkr Biosimilar Gp Llc

No Data

Ownership Network Relation of Kkr Biosimilar Gp Llc

Kkr Biosimilar Gp Llc Owned Company Details

What does Coherus BioSciences Inc do?

Who are the key executives at Coherus BioSciences Inc?

Kkr Biosimilar Gp Llc is the 10 percent owner of Coherus BioSciences Inc. Other key executives at Coherus BioSciences Inc include director & President and CEO Dennis M Lanfear , Chief Financial Officer Mcdavid Stilwell , and See Remarks Bryan J Mcmichael .

Coherus BioSciences Inc (CHRS) Insider Trades Summary

Over the past 18 months, Kkr Biosimilar Gp Llc made no insider transaction in Coherus BioSciences Inc (CHRS). Other recent insider transactions involving Coherus BioSciences Inc (CHRS) include a net sale of 223,100 shares made by Dennis M Lanfear ,

In summary, during the past 3 months, insiders sold 0 shares of Coherus BioSciences Inc (CHRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 223,100 shares of Coherus BioSciences Inc (CHRS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 223,100 shares.

Coherus BioSciences Inc (CHRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Coherus BioSciences Inc Insider Transactions

No Available Data

Kkr Biosimilar Gp Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Kkr Biosimilar Gp Llc. You might contact Kkr Biosimilar Gp Llc via mailing address: 9 West 57th Street, Suite 4200, New York Ny 10019.

Discussions on Kkr Biosimilar Gp Llc

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.